About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Clinical Performance Evaluation of DxN HBV Assay

Clinical Performance Evaluation of DxN HBV Assay

NCT03123159·10 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Beckman Coulter, Inc.

Same as brief summary.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Subject is 18 years of age or older
Subject has serological evidence of chronic HBV infection, and measurable HBV-DNA and ALT at baseline
Subject will undergo treatment with tenofovir or entecavir for a minimum of 48 weeks

You may not be if

Co-infection with HIV or HCV at enrollment
Subject has decompensated liver disease or liver cancer
Prior participation in study
Current or planned participation in an investigational drug or device study

The record

StatusTerminated

PhaseNo phase

Taking part60

StartedMay 2014

UpdatedJul 12, 2018

Conditions

Where10

Scripps Clinic
La Jolla, California, United States
University of Minnesota Medical School
Minneapolis, Minnesota, United States
University of Mississippi Medical Center
Jackson, Mississippi, United States